Oyster Point Pharma, Inc.
Salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine

Last updated:

Abstract:

The present invention relates to the stereospecific synthesis of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, its salt forms, and novel polymorphic forms of these salts.

Status:
Grant
Type:

Utility

Filling date:

25 Apr 2018

Issue date:

24 Sep 2019